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This project proposes to enhance technology aimed at improving osseointegration following 
dental implant. Specifically, we focus on the delivery of plasmid DNA (pDNA) using 
nanostructured hydroxyapatite particles coated on titanium surfaces. Our hypothesis is that 
localized expression of osteoinductive proteins will improve healing time and facilitate 
osseointegration, as well as enhance the efficacy of placing implants in porous type 4 bone.  
To evaluate the feasibility of intercellular gene delivery off titanium surfaces, we 
employed a reporter system of green fluorescent protein (GFP) pDNA-NanoCaP particles coated 
on a titanium surface.  MG63 osteoblast cells were seeded on this surface, and later assayed for 
GFP expression. Twenty-four substrates were assessed: experimental group 2 (Exp2, 400 µl 
NanoCaP/ 8 µl pDNA) substrates group, demonstrated significantly higher GFP expression 
values compared to the control (Ctl, 200 µl of ddH2O and 4 µl of pDNA) and Exp (200 µl of 
NanoCaP and 4 µl of pDNA) groups.  
Our data show that the coated NanoCaP/pDNA complex can transfect plated cells and 
that the applied amount of NanoCaPs is critical. In conclusion, we have successfully shown the 
feasibility of a non-viral approach to deliver plasmid DNA from titanium surfaces and suggest 
that further optimization is needed. 
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1.0  INTRODUCTION 
 
1.1 DEFINITION 
 
 
Osseointegration is the process by which clinically asymptomatic rigid fixation of alloplastic 
materials such as titanium is achieved and maintained in bone during functional loading (T. 
Albrektsson, Johansson, C., Sennerby, L,, 2000). This definition does not clarify the biological 
processes controlling bone formation and bone maintenance at the bone-to-implant interface, nor 
the cellular and molecular cascades triggered by site preparation and placement of the implant 
(Table-I). The result is primary bone healing, and bone deposition around the implant. This 
process is both time-dependent and dynamic, with maximum bone deposition achieved by 3-4 
months. After this time, the bone-to-implant interface is maintained by lifelong remodeling 
cycles of bone resorption and apposition. 
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Table 1:  Timeline for Bone Healing Process 
 
TIME LINE EVENTS 
Up to 72 hours Blood clot formation and platelet activation 
Up to 4 weeks Formation of granulation tissue; angiogenesis and fibroplasia 
3 weeks to 2 months Woven bone formation 
2 months to 4 months Replacement with lamellar bone 
4 months onwards On-going bone remodeling 
 
Osseointegration is temporally controlled. Johansson et al. demonstrated that there is a sparse 
bone-to-implant contact in the first weeks after implant insertion (Johansson, 1987). Direct 
contact and increased resistance to torque removal takes place three months post-implant 
insertion. Moreover, there is a gradually increasing required removal torque for up to three years 
after placement (Yamanaka, 1992). 
Currently, the success rates for endosseous dental implants are 70-85%, depending on the 
site of placement. Thus, improving the success rate is not the major focus for this study. Rather, 
the goals of the current project are twofold: 1) to accelerate the time to achieve osseointegration, 
thus expediting the healing process prior to final restoration placement 2) to provide a viable 
means of implant placement in porous bone (type 3 and 4). This can be achieved through the 
application of tissue engineering technology, thereby facilitating an osteoinductive (osteogenic) 
effect on the bone-implant interface. (T. Albrektsson & Johansson, 2001). 
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2.0  LITERATURE REVIEW 
2.1 DENTAL IMPLANT BIOMATERIALS 
 
A variety of dental implant materials are currently used in vivo, including titanium and its alloys, 
cobalt chromium alloys, austenitic Fe-Cr-Ni-Mo steels, tantalum, niobium and zirconium alloys, 
precious metals, ceramics, and polymeric materials.  
Among the aforementioned dental implant materials, the ceramics (aluminum oxide) bear 
similar interfacial events of tissue integration, corrosion resistance and biocompatibility 
compared to metallic surface oxides of titanium and chromium. 
2.1.1 Implant Coatings 
• Hydroxyapatite (HA) is frequently used as a coating, either through spin coating 
or plasma spraying, for implant or cobalt alloy substrates. HA is a naturally 
occurring inorganic component of bone, comprising calcium apatite.  HA coating 
conveys several potential advantages, such as enhancing tissue integration and 
biocompatibility.  
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• Plasma spraying, which involves spraying molten powder droplets onto the 
substrate under high temperatures (15,000⁰ C), is considered an  attractive means  
of achieving a porous/rough coating surface (Hermann H, 1988; Steinemann SG, 
1985). 
• Sandblasting techniques can provide irregular surfaces with <10 µm scale, nitric 
and hydrofluoric acids which can etch the titanium implant surface and change the 
surface chemistry, besides eliminating surface contaminations.  
 
HA coating provides an interconnected surface that has irregular surface pores which enhance 
bone anchorage on the surface for better stability (Schroeder A, 1981). Additionally, increased 
porosity usually increases the surface area, thus enhancing the bone cells’ attachment and 
supporting ionic exchange on the interface. The result is a better bone-to-implant interface and a 
stronger load-bearing capability (25%-30%) (W. P. Deporter DA, Pillar RM et al, 1986, 1988, 
1990; W. P. Deporter DA, Pillar RM et al,, 1996; Hench LL, 1982; Kirsch A, 1983; Pilliar RM, 
1991; Young FA, 1979).  
Moreover, the HA thickness is usually in the range of 50 µm, which is the ideal range for 
manufacturing. It was shown that bone cells that form close to HA surface display more 
organized distribution and produce more mineralized bone architecture (J. J. Thomas KA, Cook 
SD et al,, 1987). Nevertheless, bone formation increased in coated implant substrates as 
compared to other non-coated implant systems. This increased bone formation in turn improves 
the biomechanics and the initial load bearing of the implant structure. Also, studies showed that 
HA coated implants have the ability to possess stronger contact between HA-bone than between 
HA and the implant (Cook SD, 1987; deGroot K, 1987; K. J. Thomas KA, Cook SD et al,, 1987).  
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Since HA-coated materials exhibit relatively better integration with bone, it is imperative to 
ensure the strength of HA surface attachment.  A promising method of HA application such as 
ion-beam sputtering that produced denser and thinner coating (thickness of a few micrometers) 
may reduce the problem of  insufficient shear strength, or fatigue at the HA-implant interface 
(Lacefield, 1986).    
These coating and surface treatment techniques all additionally serve to enhance 
osteoblast differentiation and proliferation at the bone-to-implant interface, thus enhancing the 
osseointegration process. 
2.2 OSTEOBLAST 
 
Bone deposition is carried out by the osteoblast. When osteoblasts mature they are highly 
polarized, and secrete a specialized extracellular matrix comprising type I collagen, and non 
collagenous proteins such as osteopontin, osteocalcin, and bone sialoprotien (Marks, 2002).  
Osteoblastic proliferation and differentiation can be enhanced by the presence of specific 
growth factor such as bone morphogenetic protein (BMPs) that can produce a bio-mimetic 
surface material. It is needless to say that BMP is normally produced by osteoprogenitor and 
mature osteoblast cells. Experimentally, a relatively high dose of BMP is needed to produce 
effective results on bone cells, bringing into question the  high cost and the safety associated 
with it (Lieerman, 2002; Schmitt, 1990).  
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Studies demonstrated that surface roughness not only can affect cell adhesion properties but also 
can affect cell behavior. Current literature shows that increasing surface roughness can improve 
osteoblast cell attachment, alkaline phosphatase, osteocalcin, TGF-β, prostaglandin production 
and decrease cells proliferation (Boyan, 2001; Lohmann, 2002). 
The reaction to surface roughness also depends on the quality of bone architecture arrays 
(osteoblast cell arrangement) that possess a direct effect on the osseointegration process in the 
healing phase.  
 
2.3 DENSITY OF BONE 
 
Lekholm et al. defined four bone qualities in the anterior region of jawbones: Quality 1: 
homogeneous compact bone; Quality 2: a thick layer of compact bone surrounding a core of 
dense trabecular bone; Quality 3: a thin layer of cortical bone surrounding dense trabecular bone 
of favorable strength; and Quality 4, a thin layer of cortical bone surrounding a core of low-
density trabecular bone (Lekholm U Zarb GA, 1985).  
Each bone quality type has its advantages and disadvantages when it comes to primary 
stability, healing and long term prognosis. Quality 1 bone is highly mineralized and thus able to 
withstand high loads. Cortical lamellar bone heals with little interim woven bone formation, 
providing superior bone strength during the healing stage (Roberts EW, 1987; Roberts WEL, 
1993). 
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In Quality 3 bone, the use of coating technology is needed to compensate for the poor initial 
bone-to-implant contact and stability. Examples of these coatings are titanium plasma spray 
(TPS), or hydroxyapatite (HA). Each have been shown to improve both surface area, and initial 
bone-to-implant contact. Blood supply and circulation in this bone quality usually lead to faster 
healing and regeneration, because migration of the regenerative cells is easier through collateral 
blood vessels. 
In addition, initial bone-to-implant contact is 50%, therefore, coating is important in 
implant design in this bone quality, and that is to provide support for the implant healing through 
the coating which provides 20-30% more surface area and more initial trabecular bone at the 
bone-to-implant interface (Block MS at al, April 1988; Block MS, 1987).  
The healing time frame for this bone quality can take up to 6 months in order to increase 
the lamellar bone formation and mineralization. 
Quality 4 bone represents porous bone architecture, and thus poor initial stability because 
of the poor bone-to-implant contact at the time of implant placement. Healing on this bone 
quality needs more time compared to the above mentioned bone qualities; eight months or more 
of healing time may be needed to improve the trabeculation and mineralization of bone structure 
around implant, and undoubtedly, coating is needed for implant surface to improve the surface 
area (30%) and to enhance the initial healing mechanism. 
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2.4 BONE-TO-IMPLANT HEALING (OSSEOINTEGRATION) 
The process of cutting the bone to provide space for an implant creates an injury, and subsequent 
healing cascade. 
Following implant placement, the gap between the bone and the implant will fill with 
blood. This blood brings factors which will initiate the healing process, culminating eventually in 
intramembranous bone formation, (Schenk R, 1994) and de novo bone formation (Davies JE 
1998).  
In large or small defects, bone healing takes the same pattern; it all starts with blood clot 
formation, angiogenesis, osteoprogenitor cell migration, woven bone formation, compaction of 
woven bone by deposition of parallel-fibered and lamellar bone, and secondary remodeling of 
the woven bone. 
Roberts et al. found that it takes three months for the remodeling process to reach the 
balancing stage (1.5 mo for woven bone formation + 1.5 mo for turnover) at the interfacial gap 
(Roberts EW, 1987). If complete bone healing is required, then six months or more are 
necessitated, depending on the initial bone density. 
Furthermore, the cement line that normally exists between secondary osteon and pre-
existing bone has been found to be similar at a healing bone-to-implant interface. Additionally, 
the presence of extracellular matrix proteins such as osteopontin and bone sialoprotein indicates 
that the healing that occurs at this post-injury interface takes a similar pattern to the natural 
osteogenic process (McKee MD, 1993). 
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2.5 TISSUE ENGINEERING 
Tissue engineering is new field of research that relies on a combination of materials, growth 
factors and cells to regenerate diseased tissues. According to Langer and Vacanti, “tissue 
engineering is an interdisciplinary field that applies the principles of engineering and life 
sciences toward the development of biological substitutes that restore, maintain, or 
improve tissue function or produce a whole organ” (Langer). 
Scientific advances in biomaterials and stem cell technologies, as well as the knowledge 
of growth and differentiation factors and biomimetic environments, have been rapid. These 
advances have  led to the development of powerful new methods of producing tissue in vitro 
from the combined set of engineered extracellular matrices ("scaffolds"), biologically active 
molecules, and cells.  Among these treatment methods exists the use of gene therapy—namely 
the ability to deliver genes encoding proteins like growth factors, transcription factors, or 
extracellular matrix molecules, locally to somatic cells. These genes assist in regenerating the 
tissue by recapitulating the normal biological process through the expression of bioactive 
molecules (Bonadio J, 1999). 
The most prominent advantages of gene therapy over the local delivery of growth factors 
in a protein form, are increased half--life, low dose requirement, low cost, wide distribution, and 
no need for repeated applications (Wozney JM, 1998). 
Gene therapy offers different approaches for the introduction of DNA to host cells. Of the 
many approaches available, they are roughly classified into: viral and non-viral delivery 
mechanisms. 
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2.5.1 Viral Approach (Transduction) 
Viral delivery (transduction), refers to the use of a virus to transfer DNA into host cells.  
Transduction is similar to the process of “infection”, however, transduction does not end in 
disease of the cell.  
Viruses can be divided into integrating and non-integrating subtypes based on their 
influence on the cell’s genome. 
Non-integrating viruses maintain the genetic material into the nucleus as a non- 
integrated (episomal) form, instead of transferring it into the cell’s DNA. 
Adenovirus is an example of a small, non-integrating DNA virus that has the advantage 
of precisely infecting non-dividing host cell DNA at chromosome 19 (Samulski, 1991). 
 
2.5.1.1  Advantages  
 
The most important advantage of the viral approach is high transduction efficiency conveyed 
through the virus’ natural ability to infect host cells.  
 
2.5.1.2  Disadvantages   
 
The virus as a gene delivery agent has its complications, such as: endogenous recombination, 
oncogenic potential, and, most significantly, potential for toxic immunological reactivity (Ferber 
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2001; Somia N, 2000). This immunologic response is particularly critical, as it can lead to 
destruction of  the viral vector or the host cells (Ferber 2001). The significant drawbacks of viral 
gene delivery have necessitated the study and development of non-viral methods. 
 
2.5.2 Non-Viral Approach (Transfection) 
The successful transfer of DNA into the cell nucleus using non-viral vectors is defined as 
“transfection” (Graham FL, 1973; Vaheri, 1965). The great early achievements of Vaheri, 
Pagano, Graham, and van der Eb, through DEAE-dextran and calcium phosphate-mediated 
transfection techniques, opened the door for further experiments involving DNA transfer into 
cultured eukaryotic cells.  
Prior to the development of molecular biological techniques for cloning plasmid DNA, 
advancement in transfection technology were relatively slow. However, cloning techniques  
facilitated the preparation of  the DNA sequence and the production of  unlimited amounts of 
pure DNA for transfection experiments (Melton, 1984). 
Great progress in developing reporter gene technology for monitoring of the efficiency of 
DNA transfer opened new horizons for gene therapy applications. Gorman et al. established the 
reporter gene concept by using a bacterial chloramphenicol acetyltransferase (CAT) gene and an 
associated assay system. By using a reporter gene that is not endogenous to the cell, along with 
an assay system specifically sensitive for that gene product, the scientist is able to study the 
reporter gene under different conditions (Gorman, 1982; Groskreutz, 1997). 
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This approach, combined with transfection reagents such as calcium phosphate, founded 
the basics for studying promoter-enhancer sequences, trans-acting proteins such as transcription 
factors, protein/protein interactions, mRNA processing, translation, and recombination. 
Since the introduction of the CAT assay system, other reporter systems have been  developed 
including  luciferase, β-galactosidase, alkaline phosphatase and green fluorescent protein (GFP) 
(Groskreutz, 1997). 
2.5.2.1  Advantages  
 
Non-viral gene delivery methods have advantages such as tissue specific targeting (Li Y, 2004), 
ease of large scale production (Li Y, 2004; Wilson SP, 1995a; Wu D, 2003), the capacity to carry 
large DNA inserts (Corsi K, 2003), and low immunogenicity (Huard J, 2003; Li Y, 2004; Wu D, 
2003).  
2.5.2.2  Disadvantages  
 
The relative disadvantage of non-viral approaches is a decreased transfection efficiency (Huard 
J, 2003; Wu D, 2003), as compared to viral approaches.  
2.5.2.3  Transfection Efficiency Factors 
 
In general, the factors that determine the efficiency of gene transfection are: the physical and 
chemical stability of the DNA in the extracellular space, cellular uptake, DNA escape from the 
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endosomal network, cytosolic transport, and nuclear localization of the DNA for transcription 
(Chowdhury EH, 2003; Jordan M, 2004).  
2.5.2.4  Methods  
 
The methods of using non-viral gene delivery are: naked DNA injection (Hickman MA, 1994; 
Sikes ML, 1994), electroporation (Somiari S, 2000) , gene gun administration (Cheng L, 1993; 
Jiao S, 1993), cationic (Li B, 2000; Maurer N, 1999), and anionic (Fillion P, 2001; Patil SD, 
2005), lipids, cationic polymers (Kunath K, 2003; Li Y, 2004; Oster CG, 2005), peptides 
(McKenzie DL, 2000; Trentin D, 2005), and ceramic particles of calcium phosphate 
(CaP).(Batard P, 2001; Bisht S, 2005; Graham FL, 1973; Olton D, 2007b; Orrantia E, 1990; Roy 
I, 2003).   
The most important methods aforementioned are:  
• Naked DNA injection into embryonic cells, is commonly used in the production 
of transgenic organisms. However, this approach is not appropriate for studies 
requiring a high number of transfected cells (Cappechi, 1980; Hickman MA, 
1994). 
• Electroporation was first reported in 1982. This approach is often used in plant 
protoplast cells that are particularly defiant to normal gene transfer methods 
(Shigekawa, 1988; Wong, 1982). Based on the electrical stimulus of the cell 
membrane and consequent opening of pores which allow the passage of nucleic 
acid, this technique requires fine-tuning and great optimization of the electrical 
pulse for each cell type.  
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• Calcium phosphate: Extensive studies and investigations led by Graham and van 
der Eb, published in a paper in 1971, showed that calcium phosphate co-
precipitation is an effective technique for non-viral transfection. In their study, 
they evaluated cationic and anionic and phosphate concentration along with the 
pH of the solution and its effect on  transfection efficiency (Graham FL, 
1973).This precipitate is taken up by the cells via endocytosis or phagocytosis. In 
addition, the calcium phosphate provides protection against intracellular 
nucleases. 
2.5.3 Nano-scale Calcium Phosphate/pDNA complex 
One of the most attractive methods for calcium phosphate mediated transfection is the 
incorporation of pDNA with nanostructured calcium phosphate (CaP). CaP’s many clear 
advantages include its biocompatibility, biodegradability, ease of handling and adsorptive 
capacity for pDNA (Olton D, 2007a; Wilson SP, 1995b).  
Nano-scale calcium phosphate particles are typically 20 - 40 nanometers (nm) and are 
usually synthesized through mixing of CaCl2 and Na3PO4 to form a colloidal suspension of HA. 
The Ca/P ratio and pH is maintained to control the rate of nucleation and growth of the HA 
precipitates which will ultimately form a nanocrystalline calcium phosphate (Olton D, 2007a). 
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3.0  HYPOTHESIS 
Coating titanium implants with a functional system for delivery of a gene or growth factor, 
would improve and expedite osseointegration.  
 This project will propose to focus on gene delivery of plasmid DNA (pDNA) using 
nanostructured hydroxyapatite. This HA-pDNA will be coated on titanium surfaces in an attempt 
to achieve transfection of eukaryotic cells in the milieu. The therapeutic goal is the enhancement 
of osseointegration through modifying cells which migrate during the healing process, to the 
interface of titanium/bone.   
The hypothesis is that local transfer of pDNA, such as that which encodes bone 
morphogenetic protein (BMP), would be likely to improve bone healing at the implant site, and 
potentially accelerate the rate of osseointegration. Similarly, the transfer of bioactive genes at a 
site of type four (porous) bones may increase the efficiency of osseointegration and bone union 
at the site.
 
 16 
 
4.0  SPECIFIC AIM 
To assess the efficacy of precoating titanium implants with therapeutic plasmid DNA (pDNA)--
delivered using non-viral vehicles--as a means to improve and accelerate the process of 
osseointegration. Our assay systems employs a green fluorescent protein (GFP) pDNA 
complexed with NanoCaPs particles coated on a titanium surface, over which MG63 osteoblast 
cells will be grown.    
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5.0  MATERIALS AND METHODS 
 
5.1 IMPLANT SUBSTRATE (TI6AL-4V) 
                                                                                            
Titanium foil, 6AL-4V [Aluminum 5.50-6.75%, Vanadium 3.50-4.50%], 0.127mm (0.005in) 
thick, 99.99+% (metals basis) (Titanium Metal Supply, Inc.) was used as a substrate for this 
study; each substrate (total of 24) has been sectioned in 1cm X 1cm dimension.  
5.2 APPLICATION OF CAP COATING OVER TITANIUM IMPLANT SUBSTRATE 
A non-aqueous sol-gel process was used for depositing a porous CaP phase on the titanium 
implant substrate by a spin coating technique:   
Step One: The deposition of the coating fluid onto the titanium implant substrate. 
Step Two: The substrate is accelerated up to its final, desired, rotation speed (2000 rpm). 
Step Three: The substrate is spinning at a constant rate and fluid viscous forces dominate fluid 
thinning behavior. 
Step Four: The substrate is spinning at a constant rate and solvent evaporation dominates, 
enabling the formation of a thin coating.  
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Finally, the titanium implant substrate is heat-treated in air at 900˚ C for 1 hour forming a porous 
layer of hydroxyapatite. 
 
5.3 EVALUATION OF COATING TOPOGRAPHY USING SCANNING ELECTRON 
MICROSCOPY (SEM) 
Calcium phosphate (CaP) coating of the titanium surface was assessed by Philips XL-30FEG 
equipped with an EDS detector system, comprising an ultrathin beryllium window and Si (Li) 
detector operating at 25 kV.  
 Two groups were assessed:   
1. Titanium substrate coated with porous HA without NanoCaPs/pDNA complex. 
2. Titanium substrate coated with porous HA with NanoCaPs/pDNA complex. 
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Figure 1: The DNA was first added to the 
calcium precursor and then the phosphate 
precursor was added to the mix 
[NanoCaP/pDNA] 
 
Calcium precursor 
(12µl of 2M CaCl2) 
mixed with plasmid 
DNA. Total volume 
100µl.
100µl Phosphate 
precursor (280mM 
NaCl, 10mM KCl, 1.5 
mM Na3PO4, 12mM 
dextrose, 50 mM
HEPES)
pDNA condensed by 
the NanoCaPs
5.4 SYNTHESIS AND CHARACTERIZATION OF NANO-HYDROXYAPATITE 
(NANOCAPS) 
A novel aqueous solution chemistry-based technique 
used to synthesize HA: specifically, CaCl2 and Na3PO4 
will be reacted in deionized water leading to the 
immediate formation of a colloidal suspension of HA. 
The Ca/P ratio in the reacting solutions will be 
maintained at 167 to control the supersaturated state, 
thereby preventing the rapid nucleation and growth of 
the HA precipitates.  
This, combined with the addition of suitable 
pH buffering agents (50mM Hepes), will ensure an 
invariant reaction pH of 7.5 during the entire reaction.  
These conditions are suitable for synthesizing the CaP  
structures in a nanocrystalline form while also  
maintaining their chemical composition. This is critical for biocompatibility and attaining 
efficient transfection of DNA. 
A nanostructured form of hydroxyapatite (HA) was synthesized by mixing stoichiometric 
amounts of the above Ca salts and phosphate precursors [Fig-1].  4 µg of p-DNA was added to 
12µl of 2M CaCl2 solution in 100µl of water.  The mixture was added to 100µl of phosphate 
precursor (280mM NaCl, 10mM KCl, 1.5 mM Na3PO4, 12mM dextrose, 50 mM HEPES). The 
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reaction conditions, namely temperature, pH and the chemical concentration, were adjusted to 
achieve a particle size in the nanometer range.  
In the case of HA, we have determined the Ca/P ratio in the reacting solution to be 167 to control 
the supersaturated state, thereby preventing rapid nucleation and growth of the HA precipitates. 
A dilution factor of 100 was used to increase the Ca concentration in the solution such that the 
Ca/P ratio is 167 instead of 1.67 for stoichiometric HA to prevent rapid growth and coalescence.   
5.5 APPLICATION OF NANOCAP/PDNA COMPLEX OVER THE HA-COATED 
TITANIUM IMPLANT SUBSTRATE 
The NanoCap/pDNA or pDNA then added to each well/substrate. A Wallac 1450-606S Black 
Visiplate (Perkin-Elmer) plate was used, due to its special characteristics including low 
background fluorescence, minimal light scatter and reduced crosstalk. 
A total of 24 wells are divided into three main groups. Each group (n = 8) received 
different composition of NanoCaP/pDNA or pDNA complex as shown below: 
              Exp - Group:  including in each well/substrate: 200 µl of NanoCaP and 4 µl of pDNA  
Exp2 - Group:  including in each well/substrate: 400 µl of NanoCaP and 8 µl of pDNA  
   Ctl - Group:  including in each well/substrate: 200 µl of ddH2O and 4 µl of pDNA  
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5.6 DETERMINATION OF IN VITRO TRANSFECTION EFFICIENCY USING 
REPORTER GENE (GFP) 
Osteoblast (MG63) cells were cultured in 75 cm2 flasks in a humidified incubator at 37 º C and 
5%CO2; Cells were maintained at subconfluency and passaged every 2–3 days. Each 
well/substrate received 8 x104 cells that were grown in α-MEM-F12 containing 10% FBS and 
1% penicillin/streptomycin.  The cells were allowed to grow for 6 days and then tested for GFP 
expression.  
A Wallac 1420 Victor³V fluorescence plate reader (Perkin Elmer) was used to assess the 
fluorescence intensity of each substrate/well. 
 
5.7 STATISTICAL ANALYSIS 
The data were analyzed for significant (p ≤ 0.05) mean differences of fluorescent readings 
between the groups:  Ctl (control), Exp (experimental) and Exp2 (experimental-2) using one-way 
analysis of variance (ANOVA).  Post-hoc analysis for pairwise differences and identification of 
homogeneous subgroups were performed using Fisher’s Protected Least Significant Difference 
(LSD).  
Auto-fluorescence of calcium phosphate is well documented in the literature (Muddana 
HS, 2009). Therefore, titanium implant substrates with HA-coating only (Blank, n = 8) were 
used to determine the statistical means of fluorescence which might be contributed by  
background noise for Ctl, Exp and Exp2. These controls were also evaluated for pure 
determination of the cells’ native fluorescence values.  
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Blank substrates (Titanium substrate coated with porous HA without NanoCaPs/pDNA 
complex) as 4th group were also evaluated to determine if there is a significant difference among 
Ctl, Exp and Exp2 groups. 
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Figure 2: SEM images of HA-coated titanium substrate under different magnifications (67x – 500x).   
A, B: note the agglomeration of NanoCaP/pDNA complex over the surface of HA-coated implant.   
A: Note the agglomeration of NanoCaP/pDNA complex into the cracks between HA islands 
6.0  RESULTS 
 
6.1 MORPHOLOGY OF COATED SUBSTRATE UNDER ELECTRON SCANNING 
MICROSCOPY (SEM) 
The HA coating on the implant surface contains pores which play an important role in retaining 
the NanoCaP/pDNA complex. Also noticeable by SEM analysis, is the presence of grooves 
between HA islands, conveying an overall roughness. This roughness, in turn, facilitates the 
processes of cell adhesion, growth, and transfection by the NanoCaPs/pDNA. 
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Low magnification SEM shows that these grooves between HA islands seem to also serve as a 
good attachment site for the Nano-CaP/pDNA complex. [Figure 2A]. 
Higher magnification SEM analysis shows a thin film coating of NanoCaPs on the CaP 
film and also shows clusters of NanoCaP/pDNA complex [Fig3/A]. These NanoCaP/pDNA 
clusters remained in clusters on the substrate even after cell culture, as shown below in the 
fluorescence images analysis section.NanoCaP/pDNA was found to be incorporated into the 
grooves between the HA islands. In addition, NanoCaP/pDNA complex was also found on the 
pores of the HA-coating itself.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: SEM images of HA-coated titanium substrate under different magnifications (2500x – 8000x).  A, B: with 
NanoCaP/pDNA complex sinking into cracks or fissures of HA-coating.  C, D: without NanoCaP/pDNA complex. 
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6.1.1 NanoCaPs and Transfection Efficiency: 
 
Evaluation of MG63 cell transfection can be easily conducted through measurement of  green 
fluorescent protein (GFP) levels, once the pDNA encoding GFP is taken up by the cell and 
expressed.   
Twenty-four substrates were assessed for GFP expression using the Wallac 1420 
Victor³V fluorescence plate reader. Green fluorescence is indicative of the transfection efficiency 
of the various NanoCaP/pDNA treatment groups. 
              Exp - Group:  200 µl of NanoCaP and 4 µl of pDNA  
Exp2 - Group:  400 µl of NanoCaP and 8 µl of pDNA  
   Ctl - Group:  200 µl of ddH2O and 4 µl of pDNA  
 
Exp2 (400 µl NanoCaP/ 8 µl pDNA) substrates group, demonstrated significantly higher 
GFP expression values compared to the Ctl (p < .003) and Exp (p > .006) groups. 
 Moreover, Exp group (200 µl of NanoCaP and 4 µl of pDNA) showed no significant 
difference to Ctl (200 µl of plain water and 4 µl of pDNA) groups in GFP expression values. 
 A negative control group was also evaluated for GFP expression to determine and 
thereby subtract the background noise, however no significant differences were found following 
noise subtraction from the groups Exp2, Exp, and Ctl. 
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Furthermore, Blank group (Titanium substrate coated with porous HA without NanoCaPs/pDNA 
complex) demonstrated significantly low fluorescence expression values, and as a result a large 
significant difference when compared to Exp2 (p > .0004), Exp (p > .009) and Ctl (p > .017) 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Comparison of GFP expression of transfected MG63 cells: mean values for Ctl, Exp, and Exp2 groups, 
using Wallac 1420 Victor³V fluorescence plate reader.  
(n = 8 for each group, *difference is significant at p ≤ 0.05). 
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6.2 TRANSFECTION EFFICIENCY AND VISUALIZATION OF FLUORESCENCE 
Fluorescence microscopy analysis was performed to visualize the transfected MG63 cells 
expressing GFP.  A Nikon inverted microscope (Nikon Instruments, Inc.) was used. All three 
groups (Ctl, exp, Exp2), in addition to a blank group, were examined for GFP expression. Images 
were taken at 10 x magnifications to visualize a large surface area of the transfected cells plated 
on coated titanium. 
Figure 5 shows, that Exp2 group displays a significantly higher surface area of green 
fluorescence expression [Fig-5/D]. This could be due to the higher amount of NanoCaP/pDNA 
present on the substrate. 
Neither the Ctl [Fig-5/B] nor blank [Fig-5/A] groups contained any NanoCaP, however, 
the Ctl group (pDNA vector control) shows slight green fluorescence expression in MG63 cells 
compared to the blank group.  
Besides, the difference between the Exp [Fig-5/C] and Ctl [Fig-5/B] in green 
fluorescence expression values was not significant. 
Furthermore, Exp [Fig-5/C], Exp2 [Fig-5/D] groups showed a general distribution of 
NanoCaP clusters over the substrate and was always related to high green fluorescent expression 
values as measured with (Nikon) NIS-Element software. It should, however, be noted  that the 
florescence analysis was not quantitative, but rather qualitative. 
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Figure 5: Comparison of four microscopic flourescence images representing the four groups: blank (A), Ctl (B), Exp (C), Exp2 (D), 
all taken at 10x, note the scattering of pDNA/cells on Ctl group and the clusters of  NanoCaP/pDNA/cells on Exp and Exp2. 
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7.0  DISCUSSION 
 
Titanium implant surface chemistry has been studied over the years to identify the best surface in 
terms of biocompatibility and stability. It is well documented that titanium is biocompatible due 
to its bioinert chemistry (Chiang CY, 2009). In addition, the ion composition of the titanium 
surface was shown to be important to support cell growth upon coatings of substrates such as 
calcium phosphate  (Park JW, 2009 ). Furthermore, the CaP coated implants were shown to have 
a bone-to-implant contact of 77.6% +/- 5.1% after 15 years of loading (Iezzi G, 2009). 
Our study has focused on coating titanium foil 6AL-4V, using a spin coating technique; 
all substrates received the same amount of CaP particles to produce homogeneous layer 
thickness. The titanium coated substrates were examined via scanning electron microscopy to 
evaluate the pores/grooves on the surface at the micron-scale.  
SEM images showed a homogenous surface with multiple scattered grooves that formed 
the shape of an island (HA island). This calcium phosphate coating should yield a surface with 
higher roughness, which would be desirable since previous studies showed that implant surface 
roughness in three micron range could improve the differentiation of osteoblasts in vitro 
(Marinucci L, 2007). 
 30 
 
In this study, surface roughness was not quantified or measured. Future in vitro evaluation of the 
coating will be done by Atomic Force Microscopy (AFM) to evaluate the surface texture  and 
angle of the surface grooves (Catauro, Raucci, de Marco, & Ambrosio, 2006). 
A nanostructured form of hydroxyapatite (HA) was successfully synthesized by mixing 
stoichiometric amounts of the Ca-salts and phosphate precursors.  
Three groups were used in this project, each of which showed different transfection 
results reflecting different NanoCaP concentrations. High transfection efficiency was achieved as 
shown by fluorescence measurement when 400µl of NanoCaP were used, and low transfection 
values were achieved in the control group that has 4 µg of pDNA only.  
Our study showed the efficacy of using NanoCaP as a carrier method. Previous studies 
that used NanoCaPs supported the same results, which found that use of NanoCaP particles for 
transfection proved to enhance odontogenic differentiation (rat dental pulp stem cells), when 
cultured on 3-dimensional scaffolds. Furthermore, pDNA/NanoCaP complexes have been shown 
to be very effective as non-viral carriers, and were instrumental in facilitating odontogenic 
differentiation mediated by BMP-2 growth factor transfection (Yang, et al., 2008). 
The next step in this project is to incorporate the proper growth factor gene such as BMP- 
2 (osteoinductive) with the NanoCaP to form a complex over the osteoconductive HA-coated 
surface and subsequently improving and expediting bone formation.   
In previous studies, soybean trypsin inhibitor was incorporated into a biodegradable 
polymer that was coated on a titanium implant surface. The release of the protein from the 
surface improved ingrowths of bone cells. Besides, the biodegradable carrier system degraded 
completely after 11 weeks. Moreover, it was concluded that after 42 days, 76% and 71% of IGF-
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I, TGF-β1, respectively, were found in the elution fluid by ELISA (Agrawal, Pennick, Wang, & 
Schenck, 1997). 
It is well documented from the literature that the use of Gentamicin on Ti6Al4V/coated-calcium 
alginate and gelatin composite has an antibacterial affect against staphylococcus aureus—an 
advantage which in turn might improve bone formation (Xiao, Zhu, Liu, Zeng, & Xu, 2009). 
Drug release of Gentamicin on Ti6Al4V/coated-calcium alginate and gelatin composite was 
released within 0.5 hour, and it lasted for 10 days furthermore, the drug release can be extended 
up to 3 weeks period with anodized nano-tubular titanium with calcium phosphate crystals and 
antibiotic penicillin-based. 
Therefore, in addition to growth factor release from the surface of the implant, the 
incorporation of antibiotic such as Gentamicin on the titanium surface toward the collar of the 
dental implant might prove to be very beneficial.   
 Future incorporation of Gentamicin in a specified area such as the collar and the BMP 
onto the remaining surface seems a feasible approach (Brohede, et al., 2009; Catauro, et al., 
2006; Xiao, et al., 2009; Yao & Webster, 2009). 
Following this feasibility study, optimizing the concentration of BMP-2 delivery is very 
important as shown by Liu et al. They incorporated BMP-2 on a metallic titanium surface and on 
a calcium phosphate coated implant surface. The results showed implant osteoconductivity was 
the lowest when BMP-2 was adsorbed (burst-release fashion), and was improved when BMP-2 
was incorporated into calcium phosphate coating. (Liu, Enggist, Kuffer, Buser, & Hunziker, 
2007).We have used a non-viral approach to deliver plasmid DNA from titanium surfaces and 
our data is promising, showing the feasibility of the method. It would be of interest to compare 
the efficacy of a non-viral approach to viral delivery as described by Song et al., who delivered 
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an adeno-associated virus encoding BMP7 around HA-coated titanium implant in rabbit bilateral 
tibia.  
Gaps were created around the dental implant so it could be filled with Bio-Oss coated with 
adeno-BMP7.  
It was concluded that rAAV-BMP7/Bio-Oss can enhance the bone formation and trigger 
enhanced bone reaction at the bone-to-implant interface  (Song, Du, Luo, & Cao, 2008). 
Clark et al. assessed the use of TGF-β1 growth factor coated onto titanium implant and 
then placed into rabbit humerus. They demonstrated that TGF-β1 enhanced bone-to-implant 
contact at the interface by 96%, and bone ingrowths into the porous surface by 50%. 
Furthermore, their study supported the physiologic incorporation of drug into the porous surface 
instead of adsorption fashion (Clark, Moioli, Sumner, & Mao, 2008). 
In addition to TGF-β1 growth factor, rhFGF-4 was also assessed as a drug for 
osseointegration.  Franke et al. used rhFGF-4 which was injected into the femur and tibia of 
rabbits. They showed that local delivery of rhFGF-4 in a collagen sponge (altelocollagen) 
stimulated bone formation at bone-to-implant interface more than the control implant, which has 
collagen alone (Franke Stenport, Johansson, Sawase, Yamasaki, & Oida, 2003). 
Other growth factors assessed include vascular endothelial growth factor (VEGF). Wolf 
et al. incorporated the VEGF into 3-dimentional collagenous matrices on Ti6Al4V implant 
substrates. The release pattern decreased after the first 24 hours, then increased on the third day 
on heparinized matrices with VEGF, compared to pure collagen and the unmodified surface. 
Moreover, the proliferation of human dermal micro-vascular endothelial cells was enhanced after 
the release of VEGF, which in turn proved that VEGF may increase and enhance bone formation 
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and healing at the bone-to-implant interface (Wolf-Brandstetter, Lode, Hanke, Scharnweber, & 
Worch, 2006).
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8.0  CONCLUSION 
We have successfully coated the titanium implant substrate with nano-sized calcium phosphate 
(NanoCaP)/pDNA complexes, which subsequently transfected MG63 osteoblast-like cells.  
Evaluation and assessment of the MG63 cells were performed and showed that the 
NanoCaP/pDNA did adhere to the surface of the CaP and was successfully taken up by the cells. 
Our data show that the amount of NanoCaP/pDNA complex is critical to achieve efficient 
transfection.  
More studies are needed to optimize the amount of NanoCaP/pDNA that needs to be 
coated on the titanium surface. In conclusion, we have shown that NanoCaPs introduced on a 
titanium substrate have the ability to transfect cells. We suggest that this technology could be 
used to improve bone healing at the implant osteotomy site, and potentially expedite the rate of 
osseointegration. 
8.1 FUTURE STUDIES FOR THIS PROJECT MAY INVOLVE: (BY THE AUTHOR) 
- The transfer of bioactive genes at the site of type four (porous) bones may increase 
the efficiency of osseointegration and bone union at the bone-to-implant interface.  
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- Antibiotic also could be used to provide an antibacterial effect on the implant site, 
and to improve the healing process. 
- Selective osseointegration could be explored as a way to improve healing the most in 
stress-areas such as in crestal bone areas around dental implants. 
 
Further understanding and evaluation of bone proteins and growth factors is needed to take this 
project to the next level of in vitro and in vivo studies. With advanced knowledge, this 
technology could facilitate the best bone gene delivery on implant surfaces for both faster and  
better osseointegration.  
 
 
 
 
 36 
 
BIBLIOGRAPHY 
 
Agrawal, C. M., Pennick, A., Wang, X., & Schenck, R. C. (1997). Porous-coated titanium 
implant impregnated with a biodegradable protein delivery system. J Biomed Mater Res, 
36(4), 516-521. 
 
Albrektsson, T., & Johansson, C. (2001). Osteoinduction, osteoconduction and osseointegration. 
Eur Spine J, 10 Suppl 2, S96-101. 
 
Albrektsson, T., Johansson, C., Sennerby, L, (2000). Biological aspects of implant dentistry : 
osseointegration. Periodontology 2000, 2, 58-73. 
 
Batard P, J., Wurm F (2001). Transfer of high copy number plasmid into mammalian cells by 
calcium phosphate transfection. Gene, 270(1&2):61-8. 
 
Bisht S, B. G., Mitra S, Maitra A (2005). pDNA loaded calcium phosphate nanoparticles: highly 
efficient non-viral vector for gene delivery. Int J Pharm 288(1):157-68. 
 
Block MS at al (April 1988). HA-coated and grit- blasted titanium Implants in dogs. proceeding 
of the world biomaterials Congress. 
 
Block MS, K. J. K. J. (1987). Evaluation of hydroxylapatite-coated titanium dental implants in 
dogs. J Oral maxillofac Surg 45:601. 
 
Bonadio J, S. E., Patil P, et al (1999). Localized, direct plasmid gene delivery in vivo: prolonged 
therapy results in reproducible tissue regeneration. Nat Med, 5, 753. 
 
Boyan, B. D., Lohmann, C.H., Sisk, M., Liu, Y., Sylvia, V.L., Cochran, D.L., Dean, D.D. and 
Schwartz, Z. (2001). Both cyclooxygenese-1 and cyclooxygenese-2 mediate osteoblast 
response to titanium surface roughness. J. Biomed. Mater. Res. , 55, 350-359. 
 
Brohede, U., Forsgren, J., Roos, S., Mihranyan, A., Engqvist, H., & Stromme, M. (2009). 
Multifunctional implant coatings providing possibilities for fast antibiotics loading with 
subsequent slow release. J Mater Sci Mater Med, 20(9), 1859-1867. 
 37 
 
Cappechi, M. R. (1980). Cell 22, 479. 
 
Catauro, M., Raucci, M. G., de Marco, D., & Ambrosio, L. (2006). Release kinetics of 
ampicillin, characterization and bioactivity of TiO2/PCL hybrid materials synthesized by 
sol-gel processing. J Biomed Mater Res A, 77(2), 340-350. 
 
Cheng L, Z. P., Yang NS, (1993). In vivo promoter activity and transgene expression in 
mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci 
USA, 90(10):4455-9. 
 
Chiang CY, C. S., Yang WE, Hsu ML, Yung MC, Tsai ML, Chen LK, Huang HH (2009). 
Formation of TiO2 nano-network on titanium surface increases the human cell growth. 
Dent Mater, Aug;25(8):1022-9. Epub 2009 Mar 28. 
 
Chowdhury EH, S. T., Nagaoka M, Kundu AK, Akaike T  (2003). Transfecting mammalian cells 
by DNA/calcium phosphate precipitates: effect of temperature and pH on precipitation. 
Anal Biochem, 314(2):316-8. 
 
Clark, P. A., Moioli, E. K., Sumner, D. R., & Mao, J. J. (2008). Porous implants as drug delivery 
vehicles to augment host tissue integration. FASEB J, 22(6), 1684-1693. 
 
Cook SD, K. J., Thomas KA et al, (1987). Interface mechanics and histology of titanium and HA 
coated titanium for dental implant applications. Int J Oral Maxillofac Impl 2(1):15-22. 
 
Corsi K, C. F., Yahia L, Fernandes JC, (2003). Mesenchymal stem cells, MG63 and HEK293 
transfection using chitosan-DNA nanoparticles. Biomaterials 24(7):1255-64. 
 
Davies JE (1998). Mechanisms of endosseous integration. Int J Prosthodont, 11:391-401. 
deGroot K, G. R., Klien C et al, (1987). Plasma sprayed coatings of hydroxyapatite. J Biomed 
Mater Res, 21:1375-1381. 
 
Deporter DA, W. P., Pillar RM et al (1986). A histological assessment of the initial healing 
response adjacent to porous surfaced titanium alloy dental implants in dogs. J Dent Res 
5(8):1064-1070. 
 
Deporter DA, W. P., Pillar RM et al (1988). A histological evaluation of a functional 
endosseous, porous-surfaced, titanium alloy dental in the dog. J Dent Res 67:1990-1995. 
 
Deporter DA, W. P., Pillar RM et al (1990). A histological comparison in the dog of porous-
coated versus threaded dental implants. J Dent Res 69:1138-1145. 
 
Deporter DA, W. P., Pillar RM et al, (1996). A prospective clinical study in humans of an 
endosseous dental implant partially covered with a powder-sintered porous coating: 3 to 4 
years results. Int J Oral Maxillofac Impl 11:87-95. 
 
 38 
 
 
Ferber , D. (2001). Gene therapy. Safer and virus-free? . Science, 294, 
1638. 
 
Fillion P, D. A., Sayasith K, Lagace J, (2001). Encapsulation of DNA in negatively charged 
liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated 
antisense oligonucleotides. Biochim Biophys Acta 1515(1):44-54. 
 
Franke Stenport, V., Johansson, C. B., Sawase, T., Yamasaki, Y., & Oida, S. (2003). FGF-4 and 
titanium implants: a pilot study in rabbit bone. Clin Oral Implants Res, 14(3), 363-368. 
 
Gorman, C. M., Moffat, L.F . and Howard, B.H (1982). Mol. Cell. Biol, 2, 1044. 
 
Graham FL, v. d. E. A. (1973). A new technique for the assay of infectivity of human adenovirus 
5 DNA. Virology 52(2):456-67. 
 
Groskreutz, D. a. S., E.T (1997). Methods in Molecular Biology. Humana Press, NJ, 63, 11 ed. 
R. Tuan. 
 
Hench LL, C. A. (1982). Adhesion to bone I Williams DF. editor: Biocompatibility of 
orthopaedic implants, , vol 2 Boca Raton, Fla , CRC Press. 
 
Hermann H (1988). Plasma spray deposition processes. MRS Bull 60-67. 
 
Hickman MA, M. R., Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, et al, (1994). Gene 
expression following direct injection of DNA into liver. Hum Gene Ther, 5(12):1477-83. 
 
Huard J, L. Y., Peng H, Fu FH, (2003). Gene therapy and tissue engineering for sports medicine. 
J Gene Med, 5(2):93-108. 
 
Iezzi G, O. S., Pecora G, Piattelli A (2009). Histologic and histomorphometric evaluation of the 
bone response around a hydroxyapatite-coated implant retrieved after 15 years Int J 
Periodontics Restorative Dent, Feb;29(1):99-105. 
 
Jiao S, C. L., Wolff JA, Yang NS, (1993). Particle bombardmentmediated gene transfer and 
expression in rat brain tissues. Biotechnology (NY), 11(4):497-502. 
 
Johansson, C. A., T, (1987). Integration of screw implants in the rabbit. A 1 - Year follow - up of 
removal of titanium implants. International Journal of Oral and Maxillofacial Implants, 
2, 69-75. 
 
Jordan M, W. F. (2004). Transfection of adherent and suspended cells by calcium phosphate. 
Methods 33(2):136-43. 
 
 39 
 
Kirsch A (1983). the two phase implementation method using  IMZ intramobile  Cylinder. J oral 
Implanton, 11(2); 197-210, . 
 
Kunath K, v. H. A., Fischer D, Petersen H, Bickel U, Voigt K, et al, (2003). Low-molecular-
weight polyethylenimine as a non-viral vector for DNA delivery: comparison of 
physicochemical properties, transfection efficiency and in vivo distribution with high-
molecularweight polyethylenimine. J Control Release, 89(1):113-25. 
 
Lacefield, W. (1986). The coating of hydroxylapatite onto metallic and ceramic implants. 
Proceedings Trans 12th Ann Mtg Soc Biomaterials, St Paul, Minn, June. 
 
Langer, R. V. J. Tissue engineering. Science, 260, 920-6;. 
 
Lekholm U Zarb GA (1985). patient selection and preparation. In Branemark P .I, Zarb GA, 
alberktsson T, editors:  tissue- integrated prostheses,Chicago, quintessence, p 201. 
 
Li B, L. S., Tan Y, Stolz DB, Watkins SC, Block LH, et al, (2000). Lyophilization of cationic 
lipid-protamine-DNA (LPD) complexes. J Pharm Sci, 89(3):355-64. 
 
Li Y, O. M., Pelisek J, Roedl W, (2004). Stability and release characteristics of poly (D, L-
lactide-co-glycolide) encapsulated CaPi- DNA coprecipitation. Int J Pharm 269(1):61-
70. 
 
Lieerman, J. R., Daluiski, A. and Einhorn, T.A. (2002). The role of growth factors in the repair 
of bone. Biology and clinical applications. J Bone and Miner. Res. , 17, 997-978. 
 
Liu, Y., Enggist, L., Kuffer, A. F., Buser, D., & Hunziker, E. B. (2007). The influence of BMP-2 
and its mode of delivery on the osteoconductivity of implant surfaces during the early 
phase of osseointegration. Biomaterials, 28(16), 2677-2686. 
 
Lohmann, C. H., Tandy, E.M., Sylvia, V. L., Hell-Vocke, A. K., Cochran, D. L., Dean, D. D., 
Boyan, B. D. and Schwartz, Z. (2002). Response of normal female human osteoblasts 
(NHOst) to 17beta-estradiol is modulated by implant surface morphology. J. Biomed. 
Mater. Res., 62, 204-213. 
 
Marinucci L, B. S., Becchetti E, Belcastro S, Guerra M, Calvitti M, Lilli C, Calvi EM, Locci P 
(2007). Effect of titanium surface roughness on human osteoblast proliferation and gene 
expression in vitro. Int J Oral Maxillofac Implants, Jan-Feb;22(1):19. 
 
Marks, S. C. a. O., P.R., Bilezikian, J P., Raisz, L. G. and Rodan, G. A., Eds., (2002). Structure 
and development of the skeleton, In Principiles of bone Biology. Academic Press, New 
York, pp. 3-15. 
 
Maurer N, M. A., Palmer L, Monck MA, Mok KW, Mui B, et al, (1999). Lipid-based systems 
for the intracellular delivery of genetic drugs. Mol Membr Biol 16(1):129-40. 
 40 
 
 
McKee MD, N. A. (1993). Ultrastructural, cytochemical and immunocytochemical studies on 
bone and its interfaces. Cells and Materials 3:219-243. 
 
McKenzie DL, K. K., Rice KG (2000). A potent new class of reductively activated peptide gene 
delivery agents. J Biol Chem, 275(14):9970-7. 
 
Melton, D. e. a. (1984). Nucl. Acids. Res, 12, 7035. 
 
Muddana HS, M. T., Adair JH, Butler PJ (2009). Photophysics of Cy3-Encapsulated Calcium 
Phosphate Nanoparticles. Nano Lett, Apr;9(4):1559-66. 
 
Nikon, I. I. NIS-Elements. 
 
Olton D, L. J., Wilson ME, Rogers T, Close J, Huang L, Kumta PN, Sfeir C (2007a). 
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of 
the synthesis parameters on transfection efficiency. Biomaterials Feb ,28(6):1267-79. 
 
Olton D, L. J., Wilson ME, Rogers T, Close J, Huang L, Kumta PN, Sfeir C (2007b). 
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of 
the synthesis parameters on transfection efficiency. Biomaterials, Feb ,28(6):1267-79. 
 
Orrantia E, C. P. (1990). Intracellular distribution of DNA internalized through calcium 
phosphate precipitation. Exp Cell Res, 190(2)170-4. 
 
Oster CG, K. N., Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SH, et al, (2005). Cationic 
microparticles consisting of poly(lactide- co-glycolide) and polyethylenimine as carriers 
systems for parental DNA vaccination. J Control Release, 104(2):359-77. 
 
Park JW, J. J., Lee CS, Hanawa T (2009 ). Osteoconductivity of hydrophilic microstructured 
titanium implants with phosphate ion chemistry. Acta Biomater, Jul;5(6):2311-21. Epub 
2009 Feb 27. 
 
Patil SD, R. D., Burgess DJ, (2005). Biophysical characterization of anionic lipoplexes. Biochim 
Biophys Acta 1711(1):1-11. 
 
Pilliar RM, D. D., Watson PA et al (1991). Dental implant design-effect on bone remodeling. J 
Biomed Mater Res, 25:467-483. 
 
Roberts EW, T. P., Brezniak, N et al (1987). bone physiology and metabolism. J calig Dent 
Assoc 15:54-61, 1987. 
 
Roberts WEL (1993). fundamental principles of bone physiology, metabolism and loading In 
Naert I, van Steenberghe D, worhengton P editors: Osseointegration in oral 
rehabitation,, Carol Stream, IL., Quintessence., pp157-170. 
 41 
 
 
Roy I, M. S., Maitra A, Mozumdar S (2003). Calcium phosphate nanoparticles as novel non-viral 
vectors for targeted gene delivery. Int J Pharm, 250(1):25-33. 
 
Samulski, R. J. e. a. (1991). Targeted integration of adeno-associated virus (AAV) into human 
chromosome 19. EMBO J, 10,6. 
 
Schenk R, H. E., Brighton CT, Friedlander G, Lane JM, editors. Rosemont,IL: (1994). Histologic 
and ultrastructural features of fracture healing. In: Bone formation and repair. American 
Academy of Orthopaedic Surgeons., pp. 117-146. 
 
Schmitt, J. M., Hwang, K., Winn, S.R. and Hollinger, J.O. (1990). Bone morphogenetic proteins: 
an update on basic biology and clinical relevance. J Orthop.Res, 17,269-278. 
 
Schroeder A, V. d. Z. E., Stich H et al, (1981). the reactions of bone, connective tissue and 
epithelium to endosteal implants with titanium sprayed surfaces. J Maxillofac Surg, 9:15-
25. 
 
Shigekawa, K. a. D., W.J (1988). BioTechniques, 6, 742. 
 
Sikes ML, O. M. J. B., Finegold MJ, Ledley FD, (1994). In vivo gene transfer into rabbit thyroid 
follicular cells by direct DNA injection. Hum Gene Ther, 5(7):837-44. 
 
Somia N, V. I. (2000). Gene therapy: trials and tribulations. Nat Rev Genet, 1, 91. 
 
Somiari S, G.-M. J., Drabick JJ, Gilbert RA, Heller R, Jaroszeski MJ, et al, (2000). Theory and 
in vivo application of electroporative gene delivery. Mol Ther 2(3):178-87. 
 
Song, K., Du, J. M., Luo, R. H., & Cao, Y. G. (2008). [Effect of Bio-Oss loading with rAAV-
BMP7 on regeneration of bone defects around dental implant]. Hua Xi Kou Qiang Yi Xue 
Za Zhi, 26(4), 421-424, 429. 
 
Steinemann SG, P. S., Muller ME (1985). Titanium alloys as metallic biomaterials. In Lutjering 
G, Zwicker U, Bunk Weditors. Proceeding of the 5th international Conference on 
titanium, . Dutsch gref MaterialKundle eV, Vol 2 1327-1334. 
 
Thomas KA, J. J., Cook SD et al, (1987). The effect of surface macrostructure and 
hydroxylapatite coating on the mechanical strengths and histologic profiles of titanium 
implant materials. J Biomed Mater Res, 21:1395-1414. 
 
Thomas KA, K. J., Cook SD et al, (1987). Effect of surface microtexture and hydroxylapatite 
coating on the mechanical strengths and histologic profiles of titanium implant materials. 
J Biomed Mater Res, 21 (12): 1395-1414. 
 
 42 
 
Trentin D, H. J., Hall H, ( 2005). Non-viral gene delivery for local and controlled DNA release. J 
Control Release, 102(1):263-75. 
 
Vaheri, A. a. P., J.S (1965). Virology 27, 434. 
 
Wilson SP, L. F., Wilson RE, Housley PR, (1995a). Optimization of calcium phosphate 
transfection for bovine chromaffin cells: relationship to calcium phosphate precipitate 
formation. Anal Biochem, 226(2): 212-20. 
 
Wilson SP, L. F., Wilson RE, Housley PR, (1995b). Optimization of calcium phosphate 
transfection for bovine chromaffin cells: relationship to calcium phosphate precipitate 
formation. Anal Biochem 226(2): 212-20. 
 
Wolf-Brandstetter, C., Lode, A., Hanke, T., Scharnweber, D., & Worch, H. (2006). Influence of 
modified extracellular matrices on TI6AL4V implants on binding and release of VEGF. J 
Biomed Mater Res A, 79(4), 882-894. 
 
Wong, T. K. a. N., E (1982). Biochem. Biophys. Res. Commun, 107, 584. 
 
Wozney JM, R. V. (1998). Bone morphogenetic protein and bone morphogenetic protein gene 
family in bone formation and repair. Clin Orthop Relat Res, 26. 
 
Wu D, R. P., Grande DA, (2003). Gene therapy and tissue engineering in repair of the 
musculoskeletal system. J Cell Biochem, 88(3):467-81. 
 
Xiao, J., Zhu, Y., Liu, Y., Zeng, Y., & Xu, F. (2009). A composite coating of calcium alginate 
and gelatin particles on Ti6Al4V implant for the delivery of water soluble drug. J Biomed 
Mater Res B Appl Biomater, 89B(2), 543-550. 
 
Yamanaka, E., Tjellstrom, A., Jacobsson, M. & Albrektsson, T, (1992). Long - term observations 
on removal torque of directly bone-anchored implants. Transplants and Implants in 
Otology, II.Ingelheim: Kugle. 
 
Yang, X., Walboomers, X. F., van den Dolder, J., Yang, F., Bian, Z., Fan, M., et al. (2008). Non-
viral bone morphogenetic protein 2 transfection of rat dental pulp stem cells using 
calcium phosphate nanoparticles as carriers. Tissue Eng Part A, 14(1), 71-81. 
 
Yao, C., & Webster, T. J. (2009). Prolonged antibiotic delivery from anodized nanotubular 
titanium using a co-precipitation drug loading method. J Biomed Mater Res B Appl 
Biomater. 
 
Young FA, S. M., Kresch CH, (1979). Porous titanium endosseous dental implants in Rhesus 
monkeys: microradiography and histological evaluation. J Biomed Mater Res 13:843-856 
 
 
